GO
Loading...

Roche Holding AG

More

  • LONDON, July 22- European shares bounced back on Tuesday on some strong earnings reports and after signs of cooperation between Russia and other nations in investigating the shooting down of a Malaysian airliner over Ukraine.

  • European shares bounce back as Ukraine tension ease Tuesday, 22 Jul 2014 | 11:25 AM ET

    LONDON, July 22- European shares rose on Tuesday on some strong earnings reports and signs of improved cooperation from Ukraine's pro-Russian rebels over the Malaysian Airlines plane shot down four days ago.

  • *ARM Holdings surges after strong results. LONDON, July 22- European equities bounced back on Tuesday partly in response to signs of improved cooperation from Ukraine's pro-Russian rebels who have agreed to hand over the black boxes from the Malaysian plane downed in Ukraine last week.

  • CHICAGO, July 21- All too often, I see investors heading in the wrong direction en masse. The Energy SPDR, which charges 0.16 percent for annual management expenses and holds Exxon Mobil Corp, Chevron Corp and Schlumberger NV, has climbed 22 percent in the past 12 months, with nearly one-third of that gain coming in the three months through July 18.

  • Business events scheduled for the coming week Thursday, 17 Jul 2014 | 1:53 PM ET

    WASHINGTON— Labor Department releases Consumer Price Index for June, 8:30 a.m.; National Association of Realtors releases existing home sales for June, 10 a.m.. GENEVA— Credit Suisse, the second-largest bank in Switzerland behind UBS, reports its second quarter results before the opening of trading in Zurich.

  • ZURICH, July 16- Roche's experimental drug crenezumab failed to delay a decline in thinking and memory skills in people with Alzheimer's disease, a result likely to bolster a growing belief that drugs need to be given in earlier stages of the disease to show a benefit.

  • Roche Alzheimer's drug fails main goals in mid-stage study Wednesday, 16 Jul 2014 | 11:30 AM ET

    ZURICH, July 16- Roche said its experimental Alzheimer's drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients' decline.

  • Genentech Alzheimer's drug misses goals in studies Wednesday, 16 Jul 2014 | 11:00 AM ET

    Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people. Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • NEW YORK, July 14- U.S. stocks were poised for a higher open on Monday after the latest flurry of merger activity and earnings from Citigroup, putting the S&P 500 on track to rebound from its worst weekly decline since April.

  • US STOCKS-Futures higher on M&A after down week Monday, 14 Jul 2014 | 7:40 AM ET

    *Shire accepts Abbvie takeover offer. *London- listed drugmaker Shire Plc succumbed to an increased 31 billion pounds takeover offer from Abbvie Inc, ending a long-running courtship largely motivated by tax rates. U.S.-listed shares of Shire rose 2.4 percent to $255.10 while Abbvie shed 0.7 percent to $54.56 in premarket trade.

  • NEW YORK, July 10- A U.S. court on Thursday rejected an appeal by Taiwan- based AU Optronics Corp of the $500 million criminal fine the company was ordered to pay in 2012 after a conviction for price-fixing in the market for liquid crystal display panels. AU Optronics appealed it as excessive.

  • *EU shift to Avastin a threat to Novartis, Bayer profits. PARIS, July 8- French lawmakers voted on Tuesday to allow the use of Roche's cancer drug Avastin as a cheap alternative eye treatment, in a budget-minded move critics fear could put patients' health- and company profits- at risk.

  • "There's reason to think that the level of fines imposed on miscreants is not as high as it ought to be, given the harm that is done," said Bert Foer, president of the American Antitrust Institute, a group in Washington, D.C., that favors aggressive enforcement of competition laws. The institute asked the Sentencing Commission to reexamine fines a year ago.

  • LONDON, July 6- The drugs don't work- and neither does the market, when it comes to antibiotics. Totally resistant forms of the lung infection emerged in India just a few years ago and have now been detected worldwide.

  • INSIGHT-How to fix a broken market in antibiotics Sunday, 6 Jul 2014 | 4:59 AM ET

    LONDON, July 6- The drugs don't work- and neither does the market, when it comes to antibiotics. Totally resistant forms of the lung infection emerged in India just a few years ago and have now been detected worldwide.

  • A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed mixed on Wednesday as the Dow and S&P 500 pushed into uncharted territory ahead of a government jobs report.

  • NEW YORK, July 2- U.S. stock indexes were little changed on Wednesday, with the Dow industrials hovering just below 17,000, after the U.S. private sector created many more jobs than expected last month.

  • NEW YORK, July 2- U.S. stocks were set to rise slightly at the open on Wednesday, with the Dow industrials ready to pierce through 17,000, after the U.S. private sector created many more jobs than expected last month.

  • *Economist Jim O'Neill to head new antibiotics panel. LONDON, July 2- Prime Minister David Cameron called on Wednesday for global action to tackle the threat of drug-resistant superbugs and said Britain planned to take a leading role in finding ways to spur the development of new antibiotics.